Floatz logo

Incagn02390

Lymphoma, Follicular

University of Alabama at BirminghamPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Lymphoma, Follicular cohort.

Asset / SponsorPhaseRating
Humax-Cd20
Fondazione Italiana Linfomi - ETS
Phase 3BB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Insel Gruppe AG, University Hospital Bern
Phase 3BB
Sait101
Archigen Biotech Limited
Phase 3B
Inotuzumab Ozogamicin
Pfizer
Phase 3B
Bendamustine
Novartis Pharmaceuticals
Phase 3B

View all 36 →

Same molecule, other indications

Incagn02390 is also rated in:

melanomaDormant
CCC
Indicative ·
53 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
RCCDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →